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ABSTRACT
Introduction Using data from a a primary care pay- 
for- performance scheme targeting quality indicators, 
the objective of this study was to assess if people living 
with type 2 diabetes mellitus (T2DM) and severe mental 
illnesses (SMI) experienced poorer glycemic management 
compared with people living with T2DM alone, and if 
observed differences varied by race/ethnicity, deprivation, 
gender, or exclusion from the scheme.
Research design and methods Primary care data from a 
cohort of 56 770 people with T2DM, including 2272 people 
with T2DM and SMI, from London (UK), diagnosed between 
January 17, 2008 and January 16, 2018, were used. 
Adjusted mean glycated hemoglobin (HbA1c) and HbA1c 
differences were assessed using multilevel regression 
models.
Results Compared with people with T2DM only, 
people with T2DM/SMI were more likely to be of an 
ethnic minority background, excluded from the pay- for- 
performance scheme and residing in more deprived areas. 
Across the sample, mean HbA1c was lower in those with 
T2DM and SMI (mean HbA1c: 58 mmol/mol; 95% CI 57 
to 59), compared with people with T2DM only (mean 
HbA1c: 59 mmol/mol; 95% CI 59 to 60). However, HbA1c 
levels were greater in Bangladeshi, Indian, Pakistani, and 
Chinese people compared with the White British reference 
in the T2DM/SMI group. People with T2DM/SMI who had 
been excluded from the pay- for- performance scheme, 
had HbA1c levels which were +7 mmol/mol (95% CI 2 
to 11) greater than those with T2DM/SMI not excluded. 
Irrespective of SMI status, increasing deprivation and male 
gender were associated with increased HbA1c levels.
Conclusions Despite a pay- for- performance scheme 
to improve quality standards, inequalities in glycemic 
management in people with T2DM and SMI persist in those 
excluded from the scheme and by gender, ethnicity, and 
area- level deprivation.
BACKGROUND
People with severe mental illnesses (SMI), 
such as schizophrenia spectrum and bipolar 
disorders, experience large reductions in 
life expectancy, mostly from preventable 
causes.1 2 The prevalence of type 2 diabetes 
mellitus (T2DM), obesity, hypertension, and 
metabolic syndrome is markedly elevated in 
these populations. This is due to a range of 
factors which may include the side effects of 
antipsychotic medications,3 as well as living 
with a debilitating condition which may make 
self- management of health conditions more 
challenging and adverse health behaviors 
more likely.4 The impact of deprivation2 5 
Significance of this study
What is already known about this subject?
 ► People with severe mental illnesses (SMI) experi-
ence major inequalities, dying 15–20 years earlier 
than the general population, mostly from prevent-
able physical causes, with a higher prevalence of 
type 2 diabetes mellitus (T2DM) noted.
 ► There is some evidence that pay- for- performance 
schemes are associated with improvements in care.
What are the new findings?
 ► Using longitudinal data from a pay- for- performance 
scheme, we found that overall, glycemic manage-
ment was improved in people living with T2DM and 
SMI compared with people living with T2DM only, 
however other inequalities persisted.
 ► In the group with T2DM and SMI, mean HbA1c levels 
were higher in some of the minority ethnic groups 
compared with the White British reference. In ad-
dition, those excluded from the scheme had mark-
edly poorer glycemic management than those not 
excluded.
How might these results change the focus of 
research or clinical practice?
 ► Even in settings operating pay- for- performance 
schemes to incentivize high- quality care, clinicians 
should be aware that inequalities in T2DM care per-
sist, and adversely impact people living with comor-
bid SMI.
 ► Outreach approaches (rather than exclusion) may be 
needed to improve diabetic care in people living with 
T2DM comorbid with SMI, in settings operating pay- 
for- performance schemes.
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and wider social determinants may also impact on health 
behaviors such as diet and physical exercise3 6 in these 
groups.
In our recent studies we have shown that relative to the 
general population, people living with SMI have a twofold 
to threefold elevated prevalence of T2DM, further 
elevated in Black Caribbean, Black African, Bangladeshi, 
Indian, and Pakistani people.5 In a recent study in the 
USA, diabetes prevalence was also noted to be higher in 
racial/ethnic minority groups with SMI compared with 
the White non- Hispanic American reference group.7 
There is also a possibility that the presence of dispari-
ties due to SMI additively interacts with ethnic inequal-
ities to worsen health outcomes.5 8 9 This may be further 
compounded by inequalities in accessing evidence- based 
treatments for T2DM management; for example, it 
has been shown that in the UK, South Asian and Black 
people with T2DM are less likely to receive indicated 
interventions, such as intensification of diabetic treat-
ments, after persistently elevated glycated hemoglobin 
A1c (HbA1c) has been identified, compared with White 
British people.10 Previous work has also indicated worse 
glycemic management in people with T2DM in those of 
lower socioeconomic position11–13 and by race/ethnicity 
in the USA and other countries.13–15 In addition, although 
all care is free at the point of contact in the UK, one of 
the largest pay- for- performance schemes in the world 
(the Quality and Outcomes Framework (QOF)) oper-
ates, whereby family doctors/general practitioners are 
financially incentivized to deliver care on selected quality 
indicators in primary care.16 17 Although this scheme 
has led to some improvements in care, including reduc-
tions in health inequalities,18 emergency admissions,19 
and potentially better monitoring of care in people with 
SMI and T2DM,20 concerns have been raised that family 
doctors/general practitioners may remove patients from 
pay- for- performance monitoring if the targets are felt by 
the clinician to be inappropriate to the patient; this prac-
tice is known as ‘exception reporting’.16 17 Concerns have 
been raised that exception reporting may be more likely 
in people with SMI as they may be more challenging to 
manage.16 17 21
There is a gap in the literature regarding potential 
inequalities impacting on glycemic management in 
people living T2DM and SMI, and most previous work 
has been cross- sectional20 or has been impacted through 
smaller sample sizes, limiting inferences.22 Therefore, 
using data from a large primary care cohort serving an 
ethnically diverse and geographically well- defined region 
in London, UK, with 10 years’ follow- up data, including 
repeated HbA1c assessments, we sought to assess dispari-
ties in glycemic management in people living with T2DM 
and SMI, taking into account specific inequalities relating 
to ethnicity, gender, area deprivation, and primary care 
exception reporting practices. We hypothesized that the 
presence of disparities across a range of indicators (pres-
ence of SMI, ethnicity, gender, deprivation, and mental 
health exception reporting) would be associated with 




Primary care data from the London boroughs of City and 
Hackney, Tower Hamlets, and Newham were used for 
the present analyses. Primary care data are managed by 
primary care staff and include entries made by primary 
care doctors, nurses, and other clinicians. The boroughs 
are urban, inner- city areas in the top decile for depriva-
tion in East London, with high ethnic diversity. In the 
UK, most people (approximately 98%) are registered 
with a general practitioner/family doctor. General prac-
titioners coordinate physical and mental healthcare 
and take the lead in monitoring and managing T2DM, 
although they may also refer to diabetologists for addi-
tional advice. All communications related to care and 
changes to medications/prescribing are relayed back to 
the general practitioner. Since 2004 UK general practi-
tioners have been incentivized through the QOF scheme 
to maintain a registry of people with T2DM. Introduc-
tion of this scheme has improved coding for conditions 
like T2DM because of QOF financial incentives.23 Using 
primary care Read codes as defined by QOF, a cohort of 
people with newly diagnosed T2DM were identified for 
the study. The cohort for the study was defined as any 
individual with an incident diagnosis of T2DM any time 
between January 17, 2008 and January 16, 2018, aged 
40 years or older. We restricted to 10 years of glycemic 
management data (taking incident T2DM diagnosis as 
the ‘start’ point). This was undertaken to ensure higher 
data quality and also permitted an assessment of HbA1c 
management soon after diagnosis.
Exposures
The main exposure for this study was presence of SMI. 
SMI diagnoses were identified in the primary care record 
using Read codes. In general, SMI diagnoses are made 
in secondary mental healthcare services by clinicians 
according to the International Classification of Mental 
Disorders-10 (ICD-10) criteria,24 with these diagnoses 
then passed back to primary care. SMI disorders in this 
study were defined as schizophrenia- spectrum disor-
ders, bipolar disorders, or any non- organic psychoses, 
and mapped on to ICD-10 codes F2* (schizophrenia 
spectrum disorders), F30 (manic episode), F31 (bipolar 
affective disorder), and F32.3 (severe depressive episode 
with psychotic symptoms). Previous work examining the 
accuracy of identifying non- organic SMI diagnoses using 
electronic health records in primary care has indicated 
high levels of accuracy and completion.25
Outcomes
HbA1c measurements are conducted and checked 
by clinicians in primary care at regular intervals. The 
frequency of measurements may range from 3- month 
to 6- month intervals until HbA1c levels and antidiabetic 
3BMJ Open Diab Res Care 2021;9:e002118. doi:10.1136/bmjdrc-2021-002118
Epidemiology/Health services research
therapies are stable, at which point frequency of moni-
toring may change to 6 monthly.26 Repeated measure-
ments of HbA1c (mmol/mol) over time were assessed 
in the cohort from the date of T2DM diagnosis to up 
to 10 years after diagnosis, when assessed at any time 
point in the study observation window. For the analyses, 
we used the date of each HbA1c assessment (which was 
the date that HbA1c was assessed and recorded in the 
clinical record by clinicians) to explicitly model HbA1c 
assessments in a repeated measures/multilevel modeling 
framework as described in the Statistical Methods section, 
which follows.
Covariates
Demographic measures used in the study included age, 
gender, and deprivation. Area- level deprivation was 
defined according to quintiles of the Townsend depri-
vation score,27 with higher scores indicating greater 
area- level deprivation, assessed at lower super output 
area level, which has a mean of 1500 households.28 The 
Townsend score is an area- based socioeconomic depriva-
tion measure derived from the UK national census data 
on residential and car ownership, unemployment, and 
overcrowding.27 It is grouped into national quintiles of 
deprivation. In this study we scored the first fifth as the 
least deprived and the last fifth as the most deprived. 
Ethnicity is recorded in primary care electronic records 
using self- reported ethnicity based on the UK Office for 
National Statistics criteria.29 This is collected at initial 
patient registration or during routine consultations using 
standard data entry templates,29 leading to the following 
groups: White British, Irish, Black African, Black Carib-
bean, Indian, Pakistani, Bangladeshi, and Chinese. 
‘Mixed’ ethnicity groups were grouped according to 
the ethnic minority group indicated, consistent with 
approaches previously taken in national surveys of health 
of ethnic minority people in England.30 People indi-
cating ‘other’ ethnicity were excluded from the sample 
due to the heterogeneity by ethnicity within this group 
(online supplemental figure 1). In addition, we also iden-
tified people who had been ‘exception- reported’ from 
mental health QOF indicators at any time during the 
observation window. Within this context, the practice of 
exception reporting is important because it is associated 
with the exclusion of patients from pay- for- performance 
schemes such as the QOF and may be used by practices to 
avoid financial penalties.31 Primary care physicians may 
use exception reporting for a range of reasons, including 
exclusion due to non- attendance after two appoint-
ments have been sent, patient refusal, if a secondary 
care service/investigation is unavailable, if a patient does 
not tolerate medications, or if there are other clinically 
inappropriate reasons to include them in monitoring/
reporting.31 Prescriptions for antidiabetic medications 
are well captured in the primary care record, as general 
practitioners coordinate repeat prescriptions even if they 
are initiated in secondary care. Details on prescriptions 
were extracted from the primary care record, and a 
variable derived which indicated either any prescription 
of insulin (with or without oral hypoglycemic medica-
tions), any prescription of oral hypoglycemic medication 
(without insulin) and non- insulin injectable agents, or 
no antidiabetic medications (either oral or insulin), 
in the observation window. For each of the treatment 
approaches we assessed any mention of the treatment 
approach over the 10- year period. With intensification 
approaches (eg, no medication to non- insulin to insulin), 
the highest level was prioritized. Prescriptions for antipsy-
chotic medications were also noted if dispensed within 
the study observation window period. The total number 
of consultations over the study observation period was 
noted. We also estimated ‘duration of T2DM diagnosis’ 
by subtracting the date of T2DM diagnosis onset from the 
end date for the study.
Statistical methods
To assess the association of the main exposure (SMI) 
with estimated mean HbA1c, while taking into account 
the correlation of repeated HbA1c measures in the 
same individual, mixed effects regression models with 
random intercepts and slopes were used, with hierar-
chical levels which accounted for repeated measures 
(level 1) nested in individuals (level 2), further nested 
in general practices (level 3). Random intercepts were 
specified at each level, and random slopes specified for 
repeated HbA1c measures in individuals over time. We 
compared models specifying random intercepts only with 
models specifying random intercepts and random slopes 
for repeated HbA1c measurements by individuals using 
likelihood ratio tests. Likelihood ratio tests supported 
the additional specification of random slopes to models; 
therefore, all models presented in this paper are mixed 
effects models with random slopes on repeated HbA1c 
measures in individuals. To assess whether the presence 
of any of the potential disparity indicators (ethnicity, 
gender, deprivation, and mental health exception 
reporting) modified the association of SMI with mean 
HbA1c estimates, we assessed the interactions for each of 
these indicators with the SMI variable. In fully adjusted 
models, there was strong evidence supporting a statis-
tical interaction for SMI*ethnicity (Likelihood Ratio 
(LR) test χ2 (7)=16.67; p=0.02) and for SMI*exception 
reporting (LR χ2 (1)=6.62; p=0.01). Therefore, in final 
adjusted models we retained these two interactions and 
present stratum- specific estimates for these covariates. 
The xtmixed suite of commands in STATA- MP V.15 was 
used to build multilevel regression models adjusting for 
dates of HbA1c measures, age, gender, area- level depri-
vation, and with interactions (SMI*ethnicity and SMI*ex-
ception reporting), leading to adjusted estimates of mean 
HbA1c differences compared with reference groups. 
The margins command was then used to derive predicted 
mean HbA1c by ethnicity and exception reporting, 
stratified by the presence of SMI. We repeated the anal-
yses within strata of T2DM treatments (ie, restricted to 
samples receiving no pharmacological treatment, oral 
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hypoglycemic medication, or insulin). Finally, to assess 
whether receipt of antipsychotics, number of consulta-
tions, or duration of T2DM illness impacted on the esti-
mates, we repeated the analyses adding these variables 
separately to the models. Across all models, likelihood 
ratio tests were used to assess the strength of associations 
and statistical interactions.
RESULTS
Data from 124 practices ranging from 808 to 15 650 regis-
tered people (mean 5395) were used for the analysis. In 
total 56 770 people with newly diagnosed T2DM between 
January 2008 and January 2018 were included in the 
study (online supplemental figure 1 details the compo-
sition of the final cohort used for analysis). The mean 
duration of T2DM in the cohort was 3174 days or 8.7 
years. The mean duration of T2DM was similar in people 
with T2DM only (3174 days or 8.7 years) compared with 
people with T2DM/SMI (3176 days, 8.7 years). Of the 
cohort 4% (n=2272) had an SMI diagnosis.
Table 1 highlights the demographic characteristics of 
the sample. In general, in the cohort of people living with 
Table 1 Demographic characteristics of the sample
Type 2 diabetes mellitus only
Type 2 diabetes mellitus with 
severe mental illness
n % n %
Total 54 498 2272
Age (years), mean (SD)* 63 14 60 13 F=110.29, p<0.001
Gender       
  Female 24 916 46 1146 50 Pearson’s χ2=19.58, p<0.001
  Male 29 582 54 1126 50   
Ethnicity       
  White British 12 363 23 578 25 Pearson’s χ2=184.08, p<0.001
  Irish 399 1 24 1   
  Black African 7440 14 326 14   
  Black Caribbean 6710 12 455 20   
  Bangladeshi 16 105 30 569 25   
  Indian 6697 12 189 8   
  Pakistani 4319 8 110 5   
  Chinese 465 1 21 1   
Townsend deprivation score       
  Least deprived, Q1 11 597 21 306 13 Pearson’s χ2=88.57, p<0.001
  Q2 11 690 21 481 21   
  Q3 10 616 19 500 22   
  Q4 10 595 19 501 22   
  Most deprived, Q5 10 000 18 484 21   
Exception- reported†
  Never 54 457 100 1958 86 Pearson’s χ2=6631.11, p<0.001
  At least once 41 0 314 14   
Antidiabetes medications       
  Diet controlled 7084 13 269 12 Pearson’s χ2=15.84, p<0.001
  Oral/non- insulin injectable 38 529 71 1563 69   
  Insulin 8885 16 440 19   
Prescribed antipsychotics       
  None 53 245 98 608 27 Pearson’s χ2=2.25, p<0.001
  Any 1253 2 1664 73   
Total consultations over the study period, 
mean (SD)
8.9 18.7 14.5 27.1 F=186.59, p<0.001
Number of HbA1c assessments over the 
study period, mean (SD)
9.9 7.1 10.6 7.4 F=18.36, p<0.001
*On date of extraction (January 2018).
†From mental health QOF indicators.
HbA1c, glycated hemoglobin; Q, quintile; QOF, Quality and Outcomes Framework.
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both SMI and T2DM, the mean age was lower, with more 
women and more people of Black Caribbean ethnicity 
in this group, than in the group with T2DM alone. The 
group with SMI and T2DM was over- represented in 
higher deprivation areas and had a greater proportion of 
people receiving insulin and more likely prescribed anti-
psychotics than those living with T2DM alone.
Table 2 illustrates the estimated mean HbA1c in 
people with T2DM only versus T2DM/SMI, displayed 
for the full sample and then stratified by ethnicity and 
exception reporting, adjusting for all confounders. In 
the full sample with T2DM/SMI, the mean HbA1c was 
lower than in those living with T2DM only. By ethnicity, 
for the White British group with T2DM/SMI, the mean 
HbA1c was 57 mmol/mol (95% CI 55 to 58) and was 
lower than in the White British group with T2DM only 
(adjusted HbA1c: 59 mmol/mol; 95% CI 58 to 59), with 
similar trends observed in the Black Caribbean and 
Black African groups. Of note, in the group with T2DM/
SMI who had been exception- reported/excluded from 
the pay- for- performance scheme, the mean HbA1c 
levels were markedly higher (62 mmol/mol; 95% CI 61 
to 64) than those with T2DM/SMI who had not been 
exception- reported (58 mmol/mol; 95% CI 57 to 59) and 
also higher compared with those with T2DM only who 
had also been exception- reported (57 mmol/mol; 95% 
CI 52 to 62).
Across the cohort there were complex interactions 
with respect to the presence of T2DM/SMI and ethnicity. 
In people living with T2DM alone, relative to the White 
British reference group, Black Caribbean, Black African, 
Indian, and Pakistani ethnicity were associated with 
an increase in HbA1c levels, but were similar in the 
Bangladeshi group and lower in the Irish and Chinese 
groups (figure 1). In people living with both T2DM/
SMI, compared with the White British reference group, 
adjusted HbA1c levels were elevated in Indian (+3 mmol/
mol; 95% CI 0.2 to 5.2) and Chinese (+7 mmol/mol; 
95% CI 0 to 14) groups (figure 1). HbA1c levels were also 
elevated in the Pakistani (+3 mmol/mol; 95% CI −0.5 to 
6) and Bangladeshi (+1 mmol/mol; 95% CI −0.4 to 3.1) 
groups living with both T2DM/SMI compared with the 
White British reference; however, 95% CIs overlapped, 
indicating weaker evidence in support of a difference for 
these latter ethnic minority groups (figure 1). Of note, 
in the group with T2DM/SMI, exception reporting was 
associated with higher mean HbA1c levels (+7 mmol/
mol; 95% CI 2 to 11) compared with those who had not 
been exception- reported.
Tests for statistical interaction did not indicate that 
the association of SMI with HbA1c levels was modified 
by either deprivation or gender. Therefore, these are 
displayed in figure 2 for the full sample, adjusted for all 
covariates including presence of SMI. Increasing depri-
vation was associated with a relative increase in HbA1c 
levels. Men compared with women had higher HbA1c 
levels (figure 2). The association of increasing depriva-
tion with higher mean HbA1c followed a dose–response, 
with strong evidence in support of a linear trend (online 
supplemental table 1).
Associations were assessed across the sample stratified 
by T2DM treatments, with an ethnicity*SMI interaction 
fitted (figure 3). In people on diet- controlled therapy, 
the ethnicity*SMI interaction was p=0.17, in people 
prescribed oral medication the ethnicity*SMI interaction 
was p=0.10, and finally in people prescribed insulin the 
Table 2 Glycemic management in people with type 2 diabetes mellitus only and with severe mental illness, adjusted models
Estimated HbA1c (mmol/mol)
Type 2 diabetes mellitus only
Type 2 diabetes mellitus with severe mental 
illness
Mean 95% CI Mean 95% CI
Full sample 59.2 58.9 to 59.5 57.9 57.2 to 58.6
Ethnicity
  White British 58.5 58.1 to 58.9 56.5 55.1 to 57.9
  Irish 56.8 55.3 to 58.4 57.3 51.2 to 63.4
  Black African 60.2 59.8 to 60.7 58.2 56.4 to 60.0
  Black Caribbean 60.5 60.1 to 61.0 57.4 56.0 to 59.0
  Bangladeshi 58.3 57.9 to 58.7 57.7 56.3 to 59.1
  Indian 59.2 58.7 to 59.7 59.8 57.5 to 62.1
  Pakistani 61.5 60.9 to 62.0 62.0 59.1 to 64.9
  Chinese 55.9 54.5 to 57.3 61.0 54.3 to 67.7
Exception reported
  Not exception reported 59.2 58.9 to 59.5 58.0 57.1 to 59.0
  Exception reported 57.0 52.3 to 61.6 62.4 60.6 to 64.2
Full sample estimates are from multilevel regression models, adjusted for age, sex, date of HbA1c assessments, and Townsend Deprivation Index. 
For stratified estimates HbA1c was estimated from multilevel regression models, adjusted for age, sex, date of HbA1c assessments, Townsend 
Deprivation Index, SMI*ethnicity, and SMI*exception reporting.
HbA1c, glycated hemoglobin; SMI, severe mental illnesses.
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ethnicity*SMI interaction was p=0.03, indicating strong 
evidence in support of an SMI*ethnicity interaction in 
the insulin- prescribed group. Figure 3 shows that in 
contrast to people living with T2DM only, in people living 
with both T2DM/SMI, glycemic management for some 
of the ethnic minority groups was close to parity with the 
White British group. However, this was not observed in 
Bangladeshi, Pakistani, Indian, and Chinese people with 
T2DM/SMI on insulin, who displayed higher HbA1c 
levels, relative to the White British reference group.
Addition of ‘antipsychotic prescriptions’ or ‘total 
number of consultations over the observation window’ 
and ‘duration of T2DM’ variables to models had little 
effect on associations (see online supplemental figures 
1 and 2), indicating that these variables did not account 
for observed associations. Finally, models were rerun 
Figure 1 Mean HbA1c differences (mmol/mol) by ethnicity, exception reporting, and severe mental illness. Estimates adjusted 
for displayed variables (SMI*ethnicity and SMI*exception reporting interaction) and age, sex, date of HbA1c assessments, 
and area deprivation (continuous). See online supplemental table 1 for the models. HbA1c, glycated hemoglobin; SMI, severe 
mental illnesses; T2DM, type 2 diabetes mellitus.
Figure 2 Mean HbA1c differences (mmol/mol) by gender and deprivation (full sample). Estimates adjusted for displayed 
variables (gender, deprivation in ordered categories), severe mental illness*ethnicity interaction, severe mental illness*exception 
interaction, age, and date of HbA1c assessments. See online supplemental table 1 for full estimates (crude/adjusted). HbA1c, 
glycated hemoglobin; Q, quintile; REF, reference.
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without age restrictions (as people with SMI may develop 
T2DM at younger ages). These analyses did not impact 
on overall estimates (available from authors on request).
DISCUSSION
There are complex associations linked to glycemic 
management in people living with T2DM and SMI. 
First, our findings indicate that people living with T2DM 
comorbid with SMI do not necessarily experience poorer 
glycemic management compared with people living 
with T2DM only. This is consistent with previous find-
ings from other studies in the UK20 and USA,32 33 and is 
unexpected given the observation that people with SMI 
die 15–20 years earlier than the general population, 
mostly from preventable physical causes.1 2 Unlike most 
previous work which has been cross- sectional,20 32 we were 
able to use longitudinal data with repeated measures of 
HbA1c levels, up to 10 years from diagnosis. Our study 
did not directly assess the before/after effect of intro-
ducing pay- for- performance approaches in UK primary 
care; however, it is possible that this has led to improved 
care for people living with T2DM comorbid with SMI. 
Previous work has indicated that the introduction of 
pay- for- performance schemes in primary care in the UK 
may have been associated with reductions in healthcare 
inequalities.18 34 However, the scheme has also been crit-
icized, and concerns have also been raised that people 
living with multiple comorbidities are also more likely to 
be excluded from the scheme.35
A second set of findings related to the interactions with 
ethnicity in people with SMI and T2DM, which suggested 
differences across groups. In the group with T2DM/SMI, 
Bangladeshi, Indian, Pakistani, and Chinese ethnicity was 
associated with increased HbA1c levels, compared with 
the White British reference group. These differences in 
some instances were marked, ranging up to a large mean 
difference of +7 mmol/mol (95% CI 0 to 14) for the 
Chinese group with T2DM/SMI. In addition, we found 
that people living with T2DM/SMI who had been excluded 
from the pay- for- performance scheme through the prac-
tice of ‘exception reporting’ had HbA1c levels which were 
notably higher (+7 mmol/mol; 95% CI 2 to 11) compared 
with people living with T2DM/SMI who had not been 
exception- reported. This may indicate that outreach rather 
than ‘exception’ approaches are needed to effectively 
manage people with T2DM comorbid with SMI, although 
further work is needed to explore this. Irrespective of the 
presence of SMI, gender and residing in more deprived 
areas, were associated with higher HbA1c values. This is 
consistent with the wider literature13 and is noteworthy as 
people living with SMI in the cohort were also more likely to 
be residents of deprived areas. It should be noted, however, 
that while the differences relating to Chinese ethnicity and 
people who had been exception- reported were marked, 
many of the other differences in HbA1c management were 
more modest and less clinically significant.
We found that mean differences in HbA1c levels 
persisted and became more evident when analyses 
were further assessed according to diabetic treatments. 
Compared with people living with T2DM only, for some 
ethnic minority groups with T2DM/SMI, HbA1c levels 
were closer to that of the White British reference group 
across treatments. However, this was not noted in Bangla-
deshi, Indian, Pakistani, and Chinese people living with 
T2DM/SMI with a record of ever having received insulin, 
in whom HbA1c levels were noted to be higher compared 
with the White British group. Further work is needed to 
establish if there are ethnic disparities in T2DM inten-
sification strategies,10 when also taking into account the 
presence of SMI, or whether these differences reflect 
earlier onset and more rapid/severe T2DM progression 
for some groups.
Figure 3 Mean HbA1c differences by ethnicity, severe mental illness and antidiabetic treatments. Adjusted for age, sex, 
exception reporting, Townsend Deprivation Index, date of HbA1c assessment, and antipsychotic medications. See online 
supplemental table 2 for estimates. HbA1c, glycated hemoglobin; REF, reference; SMI, severe mental illness; T2DM, type 2 
diabetes mellitus.
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Observed differences by ethnicity may either indicate 
potential suboptimal management practices in the phys-
ical health of people with T2DM/SMI, which may include 
therapeutic inertia in intensifying diabetic treatments 
once high HbA1c levels are identified,10 and a higher 
risk of mortality or diabetic complications, potentially as 
result of ethnic inequalities impacting on the delivery of 
diabetes care.36 Alternatively, the findings may suggest 
more severe illness in these groups, which is then more 
challenging to manage. In a recent prospective study 
from the UK, the investigators noted that median HbA1c 
rose by 3.3 mmol/mol in Black and Asian patients in the 
first year after a psychosis diagnosis, with smaller increases 
of 1.1 mmol/mol in White patients.37 The investigators 
suggested a possibility of an ‘accelerated emergence of 
diabetes’ in people of an ethnic minority background, at 
younger ages, when diagnosed with psychotic disorders,37 
an observation also supported by cross- sectional studies.5 
Future work should aim to explore these important issues 
further, particularly as observed differences in subop-
timal glycemic management, alongside other cardiovas-
cular risk management targets (such as blood pressure, 
lipid profile, weight, tobacco cessation), are modifiable 
aspects of health management which could improve 
mortality outcomes in this group.2 38 39
The strengths of the study included its cohort design 
which enabled an assessment of glycemic management 
over time in people within the first 10 years of T2DM diag-
nosis. The large sample size of just under 60 000 people 
from primary care practices serving a large urban inner- 
city area in London, UK, ensured enhanced ethnic diver-
sity, which enabled analyses that in previous work have not 
been possible. In the UK, although pay- for- performance 
schemes may incentivize the delivery of high- quality care 
to people living with targeted health conditions in primary 
care, overall healthcare remains free at the point of contact 
and most (98%) of the population are registered to primary 
care. As we used all data from a well- defined primary care 
catchment area, the study is therefore representative of the 
underlying population and we may be reasonably certain 
that selection biases will have been minimized, with the 
cohort reflecting the sociodemographic and ethnic compo-
sition of the population resident in the catchment of the 
study. The catchment area for the study was from one UK 
city; however, the setting is fairly typical and it is likely that 
findings could be generalizable to other metropolitan 
areas nationally. The inclusion of other potential indicators 
of social exclusion/marginalization, through assessment of 
the impact of exclusion from pay- for- performance schemes 
in primary care, enabled a broader assessment of inequal-
ities impacting on glycemic management in people with 
T2DM/SMI, taking into account clinical practice. Further 
strengths of the study included our ability to assess whether 
the receipt of antipsychotic medications or the number of 
primary care consultations (as a measure of health system 
use/contacts) impacted on the associations. We found that 
although people with T2DM comorbid with SMI were more 
likely to be prescribed antipsychotic medications and had 
more consultations over the observation window compared 
with people living with T2DM alone, neither antipsychotic 
prescriptions nor consultations accounted for any of the 
observed associations for glycemic management.
There are however important limitations which need 
to be taken into consideration. Our study only assessed 
glycemic management in people with known T2DM under 
the care of general practitioners. Although primary care 
incentivization schemes ensure high levels of screening 
for T2DM,40 the finding of better glycemic management 
in the presence of SMI for some groups may be due to 
the possibility that our study only uses data from those in 
contact with healthcare providers who have been provided 
with monitoring. This is important as T2DM can be a 
‘hidden’ condition and people with these diagnoses may 
not be in contact or known to healthcare services. Related 
to this, although QOF financial incentives have in general 
improved the coding for health conditions like T2DM in 
primary care, since their introduction in 2004,23 concerns 
have been raised about primary care coding practices 
impacting on the accuracy of identifying incident T2DM 
diagnoses.23 In a previous study, estimates for T2DM were 
found to be inflated when non- diagnosis codes were used 
to identify T2DM cases.23 In the present study we only used 
Read codes for T2DM diagnoses to identify and define the 
cohort; therefore, the risk of including people in the cohort 
who did not have T2DM would have been minimized. 
Compared with many previous studies in this area, our study 
was relatively well powered to assess ethnic inequalities; 
however, for some of the smaller ethnic minority groups 
(eg, Chinese people), our study was still limited, although 
suggesting the possibility of specific ethnic disparities 
which should be explored in future work. In addition, over 
the period of the study, although QOF was the most visible 
incentive scheme, there were multiple changes to national 
and local incentivization schemes which may have further 
impacted management and screening.41–43 These occurred 
against a backdrop of changes in national treatment guid-
ance recommendations via the UK National Institute for 
Health and Care Excellence (NICE)26 and other programs 
such as the National Health Service Diabetes Prevention 
Programs (NHS DPP)44 and NHS Health Check,45 which 
may have also influenced management and screening. It 
would be beyond the scope of the current study and poten-
tially impossible to disentangle these impacts, but these 
should be borne in mind when assessing the findings from 
the present study. The basis of our study on routine elec-
tronic health records data from primary care meant that we 
could not directly assess the impact of some indicators (eg, 
socioeconomic position assessed at the individual level) on 
outcomes. Although across all models we assessed associa-
tions while considering a range of confounders (eg, finding 
that antipsychotic prescriptions, number of consultations, 
and duration of T2DM did not confound estimates), it 
is possible that unmeasured confounding may still have 
biased estimates, for example body mass index and other 
somatic comorbidities, which were not assessed. We did not 
examine changes to treatment intensification approaches 
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over time or severity of underlying T2DM, and so could not 
distinguish between these factors as potentially impacting 
on glycemic management. In addition, we only had access 
to data on mental health exception reporting; future work 
could also explore the impact of exception reporting for 
other conditions on health monitoring and management 
in people living with SMI and physical comorbidities. 
The present analyses focused on glycemic management; 
however, other indicators such as tobacco use, hyperten-
sion, weight gain, and hyperlipidemia play an important 
role in cardiovascular mortality risk38 and should be 
explored in future work for this group.
Future work should assess the impact of intersecting 
inequalities across multi- dimensions, for example the 
impact of deprivation and ethnicity, leading to inequalities 
in received care in people with T2DM comorbid with SMI. 
These are urgent concerns which, if directly tackled, could 
lead to improvements in earlier deaths in people with 
T2DM comorbid with SMI.
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